BSX Reports Tuesday With CEO Still Underwater on $9M August Buy

Boston Scientific makes medical devices for cardiac rhythm management, interventional cardiology and endoscopy. It reports third-quarter results on October 28 against a backdrop that has barely shifted since the prior preview: insiders bought heavily in August, analysts have spent three months cutting targets, and the stock at $45.69 remains roughly 5% below where CEO Michael Mahoney paid $48.33 for 186,240 shares in a single discretionary, unplanned transaction.

That insider-versus-analyst split remains the defining feature of this setup. Mahoney's $9 million open-market purchase, made without a 10b5-1 plan, was joined by two directors and the CFO across August, pushing 90-day net insider buying to roughly $9.5 million. Discretionary purchases of that scale, at CEO level, are among the more concrete conviction signals available from public filings. The stock has since recovered modestly from its post-August low, but the CEO's entry price is still above the current close.

The sell-side has moved in the opposite direction throughout. Truist cut its target from $57 to $51 on October 14, keeping its Buy rating. Barclays initiated at Equal-Weight with a $48 target on October 7. Citigroup, which downgraded to Neutral in September, trimmed its target again to $48 in early October. Wells Fargo and Oppenheimer also cut targets in late September. The mean consensus target stands at $57.82, implying roughly 27% upside to the current price, yet the direction of travel in analyst revisions has been uniformly lower. Bears point to shrinking market share in radiofrequency and cryoablation procedures, slower product uptake and rising debt levels. The bull case rests on the AFib market expanding from $9 billion to $15 billion by 2028, with recent trial results expected to lift procedure volumes meaningfully.

One structural catalyst sits beyond the earnings date. ORTEX forecasts an 80% chance that BSX's acquisition of Penumbra triggers a share-count increase in the S&P 500, which would require index trackers to buy an estimated $403 million of stock, with an announcement expected around December 8 and an effective date of December 15. A CRSP US Mid share increase carries a 70% probability and would add roughly $648 million in tracker demand. These are ORTEX forecasts, not confirmed index actions, and dates are estimated pending official announcements.

Options positioning is calm rather than defensive. The put/call ratio at 0.41 is fractionally below its 20-day average of 0.43, and well inside any range that would suggest unusual hedging. Short interest, at under 3% of the float with borrowing costs near zero and availability comfortably loose, adds nothing to the bearish thesis. The borrow market is essentially unconstricted. The Tuesday print will test whether the operating fundamentals support the CEO's conviction or confirm the more cautious read the sell-side has been building for two months.